Ambani Orgochem board meet on Oct 15, 2026 for results

What the company told the exchanges

Ambani Orgochem Limited has informed the exchange that its board of directors will meet on 15-Oct-2026. The stated agenda is to consider and approve the unaudited financial results for the half-year ended September 2026, described as the period ended September 30, 2026. For investors, this intimation matters because it sets a fixed date for the next financial disclosure and board approvals around the company’s interim performance. Such filings also help market participants track when results and related statutory decisions are expected. The disclosure is presented as a board meeting intimation, which is a standard compliance step for listed companies.

The specific agenda item: unaudited half-year numbers

The board meeting agenda explicitly mentions approval of unaudited financial results for the period ended 30-Sep-2026. Half-year results typically summarise revenue, profitability, and key line items for the first six months of the financial year, although the filing text here only confirms the intent to approve results. The company has not, in this notice text, disclosed any figures for the half-year ended September 2026. That means the market will have to wait for the outcome of the board meeting and the subsequent results filing for detailed performance data. Until then, the main actionable information is the date and the stated purpose of the meeting.

A prior board meeting was flagged for fundraising consideration

Separately, the provided notice text also states that Ambani Orgochem had informed the exchange about another board meeting to be held on 28-Sep-2026 to consider fund raising. The notice does not specify the fundraising instrument, size, pricing, or timeline. It also does not state whether any fundraising proposal was approved, deferred, or dropped. Still, the sequence of notices is notable: a fundraising consideration meeting in late September, followed by a half-year results approval meeting in mid-October. Both items are commonly tracked by shareholders because they can affect disclosures, capital structure, and near-term corporate actions.

Latest available performance snapshot from the provided data

Alongside the meeting intimation, the provided content includes a financial snapshot for Ambani Orgochem. It lists FY26 revenue of ₹243.65 crore versus ₹193.93 crore in FY25, indicating a year-on-year increase of 25.64%. It also lists operating profit of ₹4.14 crore in FY26 compared with ₹0.06 crore in FY25. The same section reports net profit of ₹1.33 crore in FY26 versus ₹0.85 crore in FY25.

The same data set also references revenue and profit figures in million rupees for other time frames. For consistency, those revenue numbers are converted here into ₹ crore (1 crore = 10 million). The most recent quarterly revenue mentioned is ₹131.59 crore (from 1,315.87 million INR). Another quarter referenced shows revenue of ₹109.15 crore (from 1,091.52 million INR).

Earnings release information shown in the dataset

The content also shows an “Earnings” section with a latest release date of 21-05-2026. It lists EPS of 0.63 for the latest quarter and revenue shown as 1.32B, which aligns with the quarterly revenue figure of 1,315.87 million INR (approximately ₹131.59 crore). It also states that for the latest quarter, the company reported net income of 11.44 million INR, which converts to ₹1.14 crore. The same section notes a comparison where net income moved from 1.91 million INR (about ₹0.19 crore) to 11.44 million INR (about ₹1.14 crore) between the referenced quarters.

These figures are presented as part of an aggregated financial data view, not as part of the board meeting notice itself. However, they provide context for what investors may look for when the September 2026 half-year numbers are released.

Profitability line items referenced in the financial FAQs

The provided content includes additional profitability metrics. It states total revenue at the end of the last reported fiscal year as 2,407.39 million INR, which converts to ₹240.74 crore. It also states full-year net income of 13.34 million INR (about ₹1.33 crore), broadly consistent with the FY26 net profit figure shown elsewhere.

On margins, it lists full-year gross profit of 671.37 million INR (about ₹67.14 crore) and last-quarter gross profit of 371.94 million INR (about ₹37.19 crore). It also lists full-year operating income of 98.83 million INR (about ₹9.88 crore) and quarterly operating income of 52.58 million INR (about ₹5.26 crore). The latest quarter’s EBITDA is shown as 71.82 million INR, or about ₹7.18 crore.

What the market typically tracks around such notices

A board meeting intimation for results is often a clear marker for the next information event. Investors generally monitor when results will be approved, when they may be published, and whether any additional board items are tagged alongside results. In this case, the disclosed purpose is narrowly focused on approving unaudited half-year results.

The separate fundraising-related board meeting notice dated for 28-Sep-2026 adds another item for shareholders to track, even though no further details are included in the provided text. Fundraising considerations can influence how investors assess balance sheet needs and future capital allocation, but the notice alone does not confirm any outcome.

Key facts table

Analysis: why this sequence matters

The immediate relevance of the 15-Oct-2026 notice is straightforward: it sets the schedule for approval of the company’s half-year financials. For a smaller listed company, timely interim results can be important for price discovery because they update investors on revenue scale, margins, and cash generation trends.

The presence of a separate fundraising consideration meeting dated 28-Sep-2026 may also keep attention on capital-related updates. Even without details on the instrument or approval status, investors tend to look for follow-through disclosures such as board outcomes, shareholder approvals (if needed), and final terms. In the short term, the next clear milestone from the provided text is the board meeting on 15-Oct-2026 and the publication of unaudited half-year results that follows.

What to watch next

Based on the disclosed agenda, the next expected update is the company’s unaudited results for the half-year ended 30-Sep-2026 after the board meets on 15-Oct-2026. Separately, any additional disclosure related to the fundraising consideration mentioned for the 28-Sep-2026 board meeting would be the next key item to track if the company publishes an outcome notice.